Brace Yourself for the

Invest during this time of opportunity while these biotech companies
are racing to get their vaccine to the world.

Open Free Account

Register with us to invest in these biotech giants and stay on top of more market news.

A search for solutions to get rid of COVID-19 is hotter than ever. Who will go down in history as the medical messiahs? As countries around the globe are experiencing second and third waves of the cruel pandemic, the first biotech company to obtain the green light for worldwide vaccine distribution will pave smooth roads ahead for its definite growth in stock value.

Seize the moment today!

A search for solutions to get rid of COVID-19 is hotter than ever. Who will go down in history as the medical messiahs? As countries around the globe are experiencing second and third waves of the cruel pandemic, the first biotech company to obtain the green light for worldwide vaccine distribution will pave smooth roads ahead for its definite growth in stock value.

With a new CEO Paul Hudson at the helm since September 2019, the company is driven to more drug company acquisitions. Coupled with their pursue for two vaccine candidates alongside their partner, GlaxoSmithKline; many expect to hear great things from Sanofi in 2021.

With a new CEO Paul Hudson at the helm since September 2019, the company is driven to more drug company acquisitions. Coupled with their pursue for two vaccine candidates alongside their partner, GlaxoSmithKline; many expect to hear great things from Sanofi in 2021.

The Latest Quarterly Results

Sanofi's business EPS grew 9.8% and sales 4.2%. Specialty care sales were up 18.3% thanks to Dupixent (medicine for severe atopic dermatitis) while vaccines grew 14.6%.

Company Revenue: $44.6B

Invest in SNY

Earnings date: 26 APRIL - 30 APRIL 2021

52 Week High/Low: 55.00/37.62

P/E Ratio: 23.61

Pfizer's miracle vaccine that is said to be more than 90% effective in preventing COVID-19 is not the only thing going on. The CEO, Albert Bourla has been steering the company in the right direction, leading them to have more than $22 billion in cash at the end of June, which can be used to buy new drugs.

Pfizer's miracle vaccine that is said to be more than 90% effective in preventing COVID-19 is not the only thing going on. The CEO, Albert Bourla has been steering the company in the right direction, leading them to have more than $22 billion in cash at the end of June, which can be used to buy new drugs.

The Latest Quarterly Results

Compared to Q4 2019, Pfizer's revenues increased by $1.2 billion (12%) to a total of $11.7 billion in Q4 2020 which reflects operational growth of 11% in this quarter.

Company Revenue: $48.6B

Invest in PFE

Earnings date: 25 APRIL - 29 APRIL 2021

52 Week High/Low: $43.08/$26.45

P/E Ratio: 19.81

Since splitting from Abbot Laboratories in 2013, AbbVie's value has risen 184% and its dividend has more than tripled. Warren Buffett's Berkshire has recently invested in 21.3 million shares with a value of over $1.86 billion. An attractive influence for an upward trend in 2021.

Since splitting from Abbot Laboratories in 2013, AbbVie's value has risen 184% and its dividend has more than tripled. Warren Buffett's Berkshire has recently invested in 21.3 million shares with a value of over $1.86 billion. An attractive influence for an upward trend in 2021.

The Latest Quarterly Results

AbbVie has announced in its earnings report for the fourth quarter of 2020 net revenues of $13.9 billion (a whopping increase of 59.2% on GAAP Basis).

Company Revenue: $40.65B

Invest in ABBV

Earnings date: 28 APRIL - 2 MAY 2021

52 Week High/Low: $113.41/$62.55

P/E Ratio: 39.46

Despite its small company size compared to other biotech giants, Moderna made headlines for developing a better vaccine at 94% efficiency, plus distribution advantages. Traders can expect to make a profit while its prices seem bearish now, while long term investors can consider the "buy and hold" technique.

Despite its small company size compared to other biotech giants, Moderna made headlines for developing a better vaccine at 94% efficiency, plus distribution advantages. Traders can expect to make a profit while its prices seem bearish now, while long term investors can consider the "buy and hold" technique.

The Latest Quarterly Results

The total revenue of Moderna for Q4 2020 was $571 million which is an increase of 3,979% compared to the $14 million for Q4 2019. Total revenue for the full‑year 2020 was $803 million.

Company Revenue: $246.7M

Invest in MRNA

Earnings date: 4 MAY - 9 MAY 2021

52 Week High/Low: $189.26/$19.31

P/E Ratio: N/A